Accelerate Diagnostics, Inc. (AXDX)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Accelerate Diagnostics, Inc. (“Accelerate” or the “Company”) (NASDAQ: AXDX). Investors who purchased Accelerate securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Accelerate has violated federal securities laws.
On October 21, 2022, Accelerate disclosed receipt of a request from the U.S. Food and Drug Administration that the Company immediately discontinue marketing and distribution of its Accelerate Arc system and related BC Kit for a particular diagnostic use. On this news, Accelerate’s stock price fell $0.62 per share, or 39.18%, to close at $0.97 per share on October 24, 2022.
If you are aware of any facts relating to this investigation or purchased Accelerate shares you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.